Fate of Myeloma Drug's Comeback Now Rests in Hands of FDA Panel

(MedPage Today) — FDA staff noted that the benefit-risk profile of belantamab mafodotin (Blenrep) in relapsed and refractory multiple myeloma remains murky given its checkered history in a briefing document released ahead of a meeting of the agency…

Source link : https://www.medpagetoday.com/hematologyoncology/myeloma/116511

Author :

Publish date : 2025-07-15 20:03:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
		1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30	31

Fate of Myeloma Drug’s Comeback Now Rests in Hands of FDA Panel

Plant Extracts Relieve Hand Osteoarthritis

States Are Walking Back Medicaid Coverage for GLP-1s

Related Posts

GLP 1s and Libido: An Effect That May Fly Under the Radar

Starving Children Screaming for Food as U.S. Aid Cuts Unleash Devastation and Death

Could Oral Microbiome Test Indicate Pancreatic Cancer Risk?

Trump Administration Begins Firing Federal Health Workers Amid Shutdown

Here’s How Much Medicaid Spends on Undocumented Immigrants

GPs Split on PSA Testing as Clearer Guidance Urged

GLP 1s and Libido: An Effect That May Fly Under the Radar

Starving Children Screaming for Food as U.S. Aid Cuts Unleash Devastation and Death

Could Oral Microbiome Test Indicate Pancreatic Cancer Risk?

Trump Administration Begins Firing Federal Health Workers Amid Shutdown

Here’s How Much Medicaid Spends on Undocumented Immigrants

GPs Split on PSA Testing as Clearer Guidance Urged

How Dentists Could Help Close the HPV Vaccination Gap

Physicists are uncovering when nature’s strongest force falters

Categories

Archives